CoChat

Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum‐resistant or ‐refractory epithelial ovarian cancer

Open access
Noonan, Anne M., Bunch, Kristen P., Chen, Jin‐Qiu, Herrmann, Michelle A., Lee, Jung‐Min, Kohn, Elise C., O'Sullivan, Ciara C., Jordan, Elizabeth, Houston, Nicole, Takebe, Naoko, Kinders, Robert J., Cao, Liang, Peer, Cody J., Figg, W. Douglas, Annunziata, Christina M. · 2016 · Cancer
Cited by 104

The DOI matches its Crossref record.

Abstract

BACKGROUND: Inhibitors of apoptosis proteins (IAPs) are key regulators of apoptosis and are frequently dysregulated in ovarian cancer. It was hypothesized that blocking IAPs with birinapant would increase tumor cell death and result in objective responses for women with platinum‐refractory and ‐resistant ovarian cancer. METHODS: In this phase 2, Cancer Therapy Evaluation Program–sponsored study, patients received birinapant at 47 mg/m 2 on days 1, 8, and 15 of 28‐day cycles. Pharmacokinetics were obtained during cycle 1. Plasma, peripheral blood mononuclear cells (PBMCs), and percutaneous tumor biopsy samples were collected before cycle 1 and after 6 weeks. The primary endpoint was an objective response or progression‐free survival lasting greater than 6 months in a mini‐max design. RESULTS: Eleven patients received birinapant; after this, accrual was terminated for lack of a clinical benefit. Birinapant was well tolerated, with predominantly grade 2 adverse events and 1 case of grade 3 lymphopenia. Pretreatment biopsy samples and PBMCs were collected; paired posttreatment biopsy samples and PBMCs were collected from 7 and 10 patients, respectively. There was consistent downregulation of cellular inhibitor of apoptosis protein 1 in tumors (P = .016) and PBMCs (P < .01). Procaspase 3 also decreased in tumors (P = .031) and PBMCs (P < .01); cleaved caspase 3 colocalized with H2A histone family member X (γ‐H2AX) in tumors after birinapant exposure. Peripheral T and B cells decreased significantly after treatment, but natural killer cells did not (P = .04, P = .05, and P = .43, respectively). CONCLUSIONS: Birinapant shows consistent target suppression in vivo without single‐agent antitumor activity in this small population. Single‐agent pharmacodynamics are necessary to understand the drug's mechanism of action and set the stage for rational combination therapy. Preclinical studies are ongoing to identify optimal synergistic combinations for future clinical trials. Cancer 2016;122:588–597. © 2015 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.29783

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 104

Metadata

Authors
Noonan, A. M., Bunch, K. P., Chen, J., Herrmann, M. A., Lee, J., Kohn, E. C., O'Sullivan, C. C., Jordan, E., Houston, N., Takebe, N., Kinders, R. J., Cao, L., Peer, C. J., Figg, W. D., & Annunziata, C. M.
Venue
Cancer
Publisher
Wiley
Published
2015-11-13
Volume
122
Issue
4
Pages
588-597
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W2173116224
Cited by
104
References
0
FWCI
9.17
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum‐resistant or ‐refractory epithelial ovarian cancer. https://app.cochat.ai/papers/10.1002/cncr.29783
The paper
Noonan, A. M., Bunch, K. P., Chen, J., Herrmann, M. A., Lee, J., Kohn, E. C., O'Sullivan, C. C., Jordan, E., Houston, N., Takebe, N., Kinders, R. J., Cao, L., Peer, C. J., Figg, W. D., & Annunziata, C. M. (2016). Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum‐resistant or ‐refractory epithelial ovarian cancer. Cancer. https://doi.org/10.1002/cncr.29783

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.